Literature DB >> 4040759

Anticytoskeletal autoantibodies in the connective tissue diseases.

J L Senécal, J M Oliver, N Rothfield.   

Abstract

The sera of 103 patients with connective tissue diseases were studied for the presence of anticytoskeletal antibodies by using an indirect immunofluorescence method. PTK2 cells fixed with paraformaldehyde and digitonin were used as substrate. Antibodies to intermediate filaments were detected in sera of 85.7% of polymyositis/dermatomyositis (PM/DM), 62.8% of systemic sclerosis, 54.5% of rheumatoid arthritis, and 37.5% of systemic lupus erythematosus patients, and in 42.5% of normal sera. High titers of these antibodies, which were IgM, were present in 30% of patients' and 5% of normal sera. Antibodies to microfilaments were present in 11.6% of patients' sera and absent in all control sera. These antibodies were IgM or IgG. The switch from an IgM to an IgG antibody was observed in 1 patient. An IgG antibody to the spindle poles and midbody of mitotic cells was present in the serum of 1 patient with the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias). Antibodies to intermediate filaments and to microfilaments occur commonly in the connective tissue diseases, particularly in PM/DM, and are not detected with substrates or fixation methods used in routine antinuclear antibody testing.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040759     DOI: 10.1002/art.1780280808

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

1.  Lack of natural antibodies in rheumatic diseases.

Authors:  J W Bijlsma; C Plater-Zyberk; P Mumford; R N Maini
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

2.  The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies.

Authors:  M Sebbag; M Simon; C Vincent; C Masson-Bessière; E Girbal; J J Durieux; G Serre
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

3.  Autoantibodies to intermediate filaments in sera of patients with Schistosoma mansoni infection.

Authors:  M W Boehme; P K Kataaha; E J Holborow
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

4.  Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study.

Authors:  B Dasgupta; O Duke; V Kyle; D G Macfarlane; B L Hazleman; G S Panayi
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

5.  Anticytoskeletal autoantibody to microfilament anchorage sites recognizes novel focal contact proteins.

Authors:  J L Senécal; S Fortin; A Roussin; F Joyal
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

6.  Antibodies to intermediate filaments in polymyalgia rheumatica/giant cell arteritis: do they reflect the underlying disease activity rather than the acute phase response?

Authors:  I Monteagudo; V Corrigall; G S Panayi; G Pountain; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

7.  Antimyenteric neuronal antibodies in scleroderma.

Authors:  S Howe; E Y Eaker; J E Sallustio; C Peebles; E M Tan; R C Williams
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

8.  Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.

Authors:  Y Yang; J Fujita; S Bandoh; Y Ohtsuki; I Yamadori; T Yoshinouchi; T Ishida
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

9.  High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so-called 'antikeratin antibodies'.

Authors:  C Vincent; G Serre; F Lapeyre; B Fournié; C Ayrolles; A Fournié; J P Soleilhavoup
Journal:  Ann Rheum Dis       Date:  1989-09       Impact factor: 19.103

10.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.